Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences. Event:H.C. Wainwright 2nd Annual Cell Therapy ConferencePresentation:March 26, 2024 at 2:00 p.m. ETFormat:Virtual fireside chat and one-on-one meetings Event:Cantor Fitzgerald’s Muscul
As you might know, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) just kicked off its latest annual results with some very...
Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.
The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Presentation Highlights Positive 24-Month Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular DystrophySAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-10
Capricor Therapeutics ( NASDAQ:CAPR ) Full Year 2023 Results Key Financial Results Revenue: US$25.2m (up by US$22.6m...
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript February 29, 2024 Capricor Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.23. Capricor Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]
Q4 2023 Capricor Therapeutics Inc Earnings Call
Company Poised for Pivotal Trial Results and FDA Discussions in 2024